Welcome to the
Biogen Newsroom

Find out how we are pioneering neuroscience to transform lives and support our communities by exploring the latest news releases, Biogen initiatives, company statements and exclusive stories.

Latest News

September 21, 2022
The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscoring the importance of these longer-term data 12-month data show earlier initiation of tofersen slowed decline across critical measures of function and strength in people diagnosed with SOD1-ALS

September 19, 2022
Biogen and Sage Therapeutics Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

Cambridge, Mass. – Sept. 19, 2022 – Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major

September 7, 2022
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus

Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to placebo Biogen is currently enrolling people with active SLE into two Phase 3 studies in 31

Lab Picture

Latest News

See Our Latest Tweets

Biogen Statements
Biogen Statements

See the latest news and statements from Biogen to stay up to date on our progress and learn about new company initiatives.

Annual Report
Annual Report

Review our annual reports to see performance highlights, financials, SEC filings, stock information and more.

Sustainability Report
ESG Report: 2021 Year in Review

Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities.

Connecting the dots in neuroscience

Can research targeting one neurological disorder drive advancements for other diseases? Chris Henderson, Head of Research at Biogen, explains how experience in one disease can accelerate development of treatments for others.

Chris Henderson
Alzheimer

Innovation in Alzheimer's

We remain focused on furthering Alzheimer’s disease research and treatment. Explore the latest information, news and stories about Alzheimer’s disease at Biogen.

health
Healthy Climate, Healthy Lives™

Biogen invests $250 million in a 20-year initiative to accelerate action on the greatest challenges of our time: climate, health and equity.

Read More
Diversity
Diversity, Equity and Inclusion

We are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients who we serve.

Read More
Corporate Responsibility

Our Commitment to Corporate Responsibility

Our impact goes beyond our medicines as we strive to improve patient health outcomes, solve social and environmental challenges, and help our employees thrive.

Request Multimedia Resources

For Media Professionals

Access Biogen logos, infographics, images, videos and more. Our media relations team will help you find exactly what you need.

Get Biogen Updates Delivered to Your Inbox

Subscribe to receive news and stories from Biogen that reflect both our dedication to transforming lives through pioneering neuroscience as well as our commitment to our communities.”

Sign Up for Biogen Alerts
Be the first to know about the latest news, updates, events and SEC Filings by signing up for Biogen email alerts.